The type I interferon system is integral to human antiviral immunity. However, inappropriate stimulation or defective negative regulation of this system can lead to inflammatory disease. We sought to determine the molecular basis of genetically uncharacterized cases of the type I interferonopathy Aicardi-Goutières syndrome and of other undefined neurological and immunological phenotypes also demonstrating an upregulated type I interferon response. We found that heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state. Cellular and biochemical assays indicate that these mutations confer gain of function such that mutant IFIH1 binds RNA more avidly, leading to increased baseline and ligand-induced interferon signaling. Our results demonstrate that aberrant sensing of nucleic acids can cause immune upregulation.
The type I interferon system is integral to human antiviral immunity. However, inappropriate stimulation or defective negative regulation of this system can lead to inflammatory disease. We sought to determine the molecular basis of genetically uncharacterized cases of the type I interferonopathy Aicardi-Goutières syndrome and of other undefined neurological and immunological phenotypes also demonstrating an upregulated type I interferon response. We found that heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state. Cellular and biochemical assays indicate that these mutations confer gain of function such that mutant IFIH1 binds RNA more avidly, leading to increased baseline and ligand-induced interferon signaling. Our results demonstrate that aberrant sensing of nucleic acids can cause immune upregulation.
Ion Gresser and colleagues first drew attention to the possibility that inappropriate exposure to type I interferon might be detrimental in mammals [1] [2] [3] . More recently, it has been proposed that mendelian disorders associated with an upregulation of type I interferon represent a distinct set of inborn errors of immunity, resulting from either inappropriate stimulation or defective negative regulation of the type I interferon response pathway 4 .
Aicardi-Goutières syndrome (AGS; MIM 225750) is an inflammatory disease particularly affecting the brain and skin, occurring as a result of mutations in any of the genes encoding the DNA exonuclease TREX1 (ref. 5) , the three non-allelic components of the RNase H2 endonuclease complex 6 , the deoxynucleoside triphosphate triphosphohydrolase SAMHD1 (ref. 7) and the double-stranded RNA (dsRNA) editing enzyme ADAR1 (ref. 8) . Some individuals with AGS do not harbor mutations in any of these six genes. AGS cases consistently demonstrate higher expression of genes induced by type I interferon, a so-called interferon signature 9 . A similar upregulation of interferon-induced transcripts is seen in the immuno-osseous dysplasia spondyloenchondromatosis (SPENCD) 10 .
To identify further monogenic type I interferonopathies, we set out to determine the molecular basis of genetically uncharacterized cases of AGS and of other undefined neurological and immunological features also demonstrating an upregulated type I interferon response. Here we show that gain-of-function mutations in IFIH1 result in a range of human disease phenotypes in which induction of type I interferon signaling is likely central to pathogenesis.
We undertook whole-exome sequencing ( Supplementary Table 1 ) in three individuals (F102, F163 and F259) with a clinical diagnosis of AGS, based on neuroradiological criteria and upregulation of cerebrospinal fluid interferon activity and/or interferon-stimulated gene (ISG) expression in peripheral blood (Supplementary Table 2 ), all of whom screened negative for mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and ADAR. Having excluded common polymorphisms listed in publically available databases, we noted that all three cases carried a single rare variant (resulting in p.Arg720Gln in F102 and p.Arg779His in both F163 and F259; Table 1) in IFIH1, which encodes a cytoplasmic helicase that mediates the l e t t e r s induction of an interferon response to viral RNA 11 . We then screened IFIH1 in other individuals negative for mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and ADAR with a phenotype indicative of AGS and in individuals with a variety of neuroimmunological features in whom we had recorded the presence of an interferon signature in peripheral blood in the absence of apparent infection ( Supplementary  Tables 2 and 3) . In this way, we identified a further five probands each heterozygous for a rare IFIH1 variant (resulting in p.Arg337Gly in F237, p.Arg779Cys in F376, p.Gly495Arg in F524, p.Asp393Val in F626 and p.Arg720Gln in F647). In total, we observed six rare variants in eight probands, with two pairs of unrelated probands each sharing the same substitution (p.Arg720Gln and p.Arg779His; Fig. 1 and Supplementary Fig. 1 ). All mutation-positive probands were born to non-consanguineous parents.
The identified variants of interest were confirmed by Sanger sequencing and were considered likely pathogenic on the basis of species conservation ( Supplementary Figs. 2 and 3) , the output of pathogenicity prediction packages ( Supplementary Table 4 ) and absence from the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) database of more than 13,000 control alleles and an in-house collection of >300 exomes. Parental samples were available for seven of the eight probands. For five of these seven, the variant was not present in either parent, although genotyping of microsatellite markers was consistent with stated paternity and maternity, indicating that the mutations had arisen de novo ( Supplementary Table 5 ). In the remaining two cases (F259_1 and F524_1), the variant detected in the proband had been paternally inherited ( Supplementary Fig. 1 ). In family F259, the variant had been transmitted by the proband's paternal grandmother (F259_3) to her son (F259_2), and, in family F524, the mutation was shown to have occurred de novo in the father (F524_2).
The majority of probands positive for mutation in IFIH1 (F102, F163, F259_1, F376 and F647) demonstrated clinical characteristics typical of neonatal AGS (Supplementary Table 2 and Supplementary Note). In contrast, two cases (F237 and F626) were developmentally normal until the second year of life, at which point they experienced rapid neuroregression. Of particular note, both affected individuals in family F524 (F524_1 and F524_2) presented a distinct phenotype of dominantly inherited spastic paraparesis. The finding of normal neuroimaging in F524_2 at the age of 29 years suggests that further cases with unexplained spasticity might harbor mutations in IFIH1 or other AGS-related genes.
To define the relationship between IFIH1 mutation status and interferon induction in vivo, we tested for an interferon signature in subjects positive for IFIH1 mutation and in their mutation-negative relatives. Samples were available from five families (F237, F259, F524, F626 and F647). All 8 mutation-positive individuals assayed, over a total of 22 data points, demonstrated robust upregulation of ISG expression (median relative quantification (RQ) = 17.43, interquartile range (IQR) = 12.27-25.77) compared with 12 family members negative for IFIH1 mutation assayed on 17 occasions (median RQ = 0.89, IQR = 0.52-1.12) and a previously standardized set of 29 control individuals (median RQ = 0.93, IQR = 0.57-1.30; Fig. 2 and Supplementary Fig. 4 ). Where measured serially, positivity for an interferon signature was sustained over time (for example, subject F524_2 was assayed on five occasions over an 18-month period). IFIH1 (interferon induced with helicase C domain 1), also known as MDA5 (melanoma differentiation-associated protein 5), is a 1,025-residue cytoplasmic viral RNA receptor. IFIH1 belongs to the RIG-I-like family of cytoplasmic DExD/H-box RNA receptors and a The mutation in the affected child was inherited from the mutation-positive clinically asymptomatic father. The proband's paternal grandmother also carries the mutation and is clinically asymptomatic. All three mutation-positive individuals demonstrate a robust interferon signature. b The mutation occurred de novo in an affected male, who then transmitted the mutation to his affected daughter. npg l e t t e r s activates type I interferon signaling through an adaptor molecule, MAVS (mitochondrial antiviral signaling protein). IFIH1 consists of N-terminal tandem caspase activation recruitment domains (2CARD) involved in activating MAVS, a central helicase domain responsible for RNA binding and RNA-dependent ATP hydrolysis, and a C-terminal domain serving as an additional RNA-binding domain ( Fig. 1) . IFIH1 uses long viral dsRNA as a platform to cooperatively assemble a core filament, which in turn promotes stochastic assembly npg l e t t e r s of the 2CARD oligomers for signaling to MAVS [12] [13] [14] . The IFIH1 filament undergoes end disassembly upon ATP hydrolysis 13 , thereby regulating the stability of the filament in a dsRNA length-dependent manner, in a potential mechanism to suppress aberrant signal activation in response to short (<~0.5-kb) cellular dsRNA.
To understand the pathogenicity of the IFIH1 mutations observed, we investigated the interferon β (IFN-β) reporter stimulatory activity of wild-type and mutant IFIH1 in human embryonic kidney (HEK) 293T cells. HEK 293T cells express low levels of endogenous viral RNA receptors, including IFIH1, as evidenced by low interferon production upon stimulation with dsRNA ( Fig. 3a) , allowing comparison of the signaling activity of ectopically expressed receptors. As expected, signaling of wild-type IFIH1 was induced only upon addition of the long (>1-kb) dsRNA analog polyinosinic:polycytidylic acid (poly I:C)
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Protein-protein interface l e t t e r s and not by short, 162-bp dsRNA (Fig. 3a) . Minimal activity was seen in the absence of exogenous RNA (Fig. 3a) . As with wild-type IFIH1, all six IFIH1 mutants displayed robust signaling in response to poly I:C (Fig. 3a) . Additionally, these mutants exhibited a marked induction of interferon signaling in response to 162-bp dsRNA (Fig. 3a) and demonstrated ~4-to 10-fold higher levels of basal signaling activity even in the absence of exogenous ligand (Fig. 3b) . As with poly I:Cinduced signaling of wild-type IFIH1, the basal and induced signaling activities of the six mutants were significantly (P < 0.005) diminished upon the introduction of additional alterations in the RNA-binding site (p.His927Ala), the filament protein-protein interface (p.Ile841Arg and p.Glu842Arg) and 2CARD (p.Arg21Ala and p.Lys23Ala) ( Fig. 3b) 13 , suggesting that the basal signaling activity of these mutants is induced by as-yet-undefined endogenous dsRNA.
Mapping of the altered residues onto the crystal structure of the 2CARD deletion construct (∆2CARD) 14 showed that these residues were located on the surface of the RNA-binding and ATP-binding sites in the Hel1 and Hel2 helicase domains (Fig. 3c) . In particular, Arg337 was in direct contact with the adenine base of ATP, stabilizing the IFIH1-ATP interaction. Substitution of Arg337 by glycine could diminish the ATP binding and hydrolysis activities of IFIH1. Asp393 and Gly495 were located within the contact distance of bound RNA. Removal of the negatively charged Asp393 residue (by p.Asp393Val) and incorporation of positively charged Arg495 (by p.Gly495Arg) near the RNA phosphate backbone could increase the intrinsic affinity of IFIH1 for dsRNA. Arg720 and Arg779 were located near the ATP-binding site but were also in proximity to the protein-protein interface in the filament (Fig. 3c) . The location of the altered residues in or near the RNA-binding and ATP-binding sites or the filament interface led us to hypothesize that the observed mutations might enhance the stability of the IFIH1 filament by increasing the intrinsic affinity between IFIH1 and dsRNA or between IFIH1 molecules in the filament or by decreasing the efficiency of ATP hydrolysis and, thus, filament disassembly rate.
To examine these possibilities, we purified individual mutants of the ∆2CARD construct, which is both necessary and sufficient for dsRNA binding, filament formation and ATP hydrolysis 14 . As previously described 12, 13 , electrophoretic mobility shift assays (EMSAs) showed that wild-type ∆2CARD cooperatively binds dsRNA in the absence of ATP but accumulates complexes of intermediate size upon Figure 3 . (c) Fraction of IFIH1-occupied sites on 112-bp dsRNA, measured from three independent EMSAs performed in the presence and absence of ATP. *P < 0.0002 (one-tailed, unpaired t test), calculated using the values at 160 nM IFIH1. Bound fraction was calculated as described 12 and fitted with the Hill equation 29 . Dissociation constants (K d ) obtained from curve fitting are shown.
npg l e t t e r s the addition of ATP (Fig. 4a) . This observation is consistent with our previous finding that ATP hydrolysis induces rapid cycles of filament disassembly and reassembly 12, 13 . Interestingly, the population of these intermediate-size complexes was markedly diminished with all six mutants, in particular with Arg337Gly, showing few or no such complexes. Measurement of ATP hydrolysis activity demonstrated that, with the exception of Arg337Gly, all the mutants hydrolyzed ATP as well as wild-type protein (Fig. 4b) . This finding rules out a lack of ATP hydrolysis as a reason for these five mutants to assemble filaments more cooperatively than wild-type protein. Quantitative analysis of the RNA-bound IFIH1 fraction from EMSAs showed that all six mutants bound RNA more efficiently than wild-type IFIH1, both in the presence and absence of cellular levels (2 mM) of ATP (Fig. 4c) .
These results suggest that ATP-independent mechanisms, i.e., tighter RNA binding and/or more stable protein-protein interaction, are likely responsible for the observed stability of the IFIH1 filament in vitro (Fig. 4a) and for higher signaling activity in cells (Fig. 3a,b) .
Here we describe 6 heterozygous IFIH1 mutations in a total of 11 individuals from 8 families, where mutation-positive status is consistently associated with an induction of type I interferon activity. The finding of de novo mutations in six families and the dominant inheritance of a clinical (F524) and/or biochemical (F524 and F259) phenotype in two families strongly suggest that these mutations are pathogenic in the heterozygous state and that IFIH1 represents a seventh gene in which mutations are associated with the AGS phenotype. Although AGS is most typically inherited as an autosomal recessive trait, rare examples due to dominant mutations in TREX1 (ref. 15 ) and ADAR 8 have been described.
A striking feature in family F259 was the marked clinical discordance between the affected child (F259_1) and his clinically asymptomatic, mutation-positive father (R259_2) and paternal grandmother (F259_3) (Supplementary Fig. 1) , despite upregulation of type I interferon signaling in all three individuals (Fig. 2) . Thus, mutation positivity and positivity for an interferon signature are not necessarily sufficient to develop an overt clinical phenotype. Notably, the same mutation (resulting in p.Arg779His), dominantly transmitted across three generations in family F259, was found to occur de novo in the proband of family F163. We and others have described both severe neurological disease and non-penetrance or age-dependent penetrance in the context of a recurrent mutation in ADAR (resulting in a p.Gly1007Arg substitution), which can also be dominantly inherited or occur as a new mutation [16] [17] [18] . Such clinical variability might be explained by modifying genetic factors or differential exposure to pathogens.
Most individuals with the autoimmune disease systemic lupus erythematosus (SLE) demonstrate an interferon signature 19, 20 , and polymorphisms in IFIH1 confer increased risk of developing SLE 21 .
In keeping with these observations, two cases in our cohort (F376 and F524_1) experienced substantial immunological disturbance consistent with lupus. The finding that the majority of IFIH1 mutation-positive individuals had no overt lupus phenotype again suggests the importance of modifying genetic or environmental factors and is concordant with a multicopy Ifih1 transgenic mouse line demonstrating chronically elevated levels of type I interferon, insufficient by themselves to initiate autoimmunity 22 .
Nejentsev et al. 23 described two canonical splice-site variants-a nonsense variant and a missense substitution-in IFIH1 as protective against type 1 diabetes (T1D) ( Supplementary Table 6 ). They postulated that these presumed loss-of-function alleles attenuate the immune response to enterovirus, a factor implicated in the pathogenesis of T1D. Unlike the variants reported in that study, all of the mutations described here are missense substitutions conferring a gain of function, and none have been documented in the NHLBI ESP database. Thus far, none of our IFIH1 mutation-positive cases have developed T1D.
Studies of the AGS-related proteins TREX1, the RNase H2 complex, SAMHD1 and ADAR1 suggest that an inappropriate accumulation of self-derived nucleic acids can induce type I interferon signaling 24, 25 . The finding of IFIH1 mutations in a similar context implicates aberrant sensing of nucleic acids as a cause of immune upregulation. The observation of enhanced baseline and ligand-induced type I interferon signaling by all six mutant alleles is consistent with our observation of increased interferon activity and/or ISG transcript levels in every mutation-positive individual tested. It is also consistent with our biochemical analyses showing that the mutants bind dsRNA more avidly and tightly than wild-type protein, albeit to a varying degree, indicating that even small differences in binding can result in a different biological phenotype. These mutations provide new insights into the function of IFIH1, which might be useful in designing therapies to potentiate host antiviral innate immunity.
The dependence of mutant basal signaling activity on dsRNA binding and filament formation suggests the presence of as-yet-undefined endogenous dsRNA capable of stimulating mutant but not wild-type receptor. In light of observed clinical non-penetrance and the rapid onset of neurological regression in the second year of life in two cases, we cannot dismiss the possibility that exogenous viral-derived RNA 26 also has a role in the disease process. We note the description of an N-ethyl-N-nitrosourea (ENU)-induced Ifih1 missense mutation in a mouse model demonstrating upregulated interferon signaling and an autoimmune phenotype 27 . In contrast to the mutants that we describe, signaling by this mutant was ligand independent.
We have previously reported an interferon signature as a reliable biomarker for AGS 9 and SPENCD 10 . The current study further emphasizes the value of searching for an interferon signature as a screening tool to identify other type I interferonopathies 4 . The recognition of such diseases is not just of academic interest, as defining a disturbance of type I interferon as primary to the pathogenesis of an aberrant phenotype suggests the possibility of anti-interferon and anti-inflammatory therapies 28 
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Affected individuals and families. All affected individuals included in this study either had a clinical and neuroradiological diagnosis of AGS associated with upregulation of cerebrospinal fluid interferon and/or ISGs in peripheral blood (an interferon signature) or a neuroimmunological phenotype in the presence of an interferon signature in peripheral blood recorded in the absence of any obvious infection. Clinical information and samples were obtained with informed consent. The study was approved by the Leeds (East) Research Ethics Committee (reference number 10/H1307/132).
Exome sequencing. Genomic DNA was extracted from lymphocytes from affected individuals and their parents by standard techniques. For whole-exome analysis, targeted enrichment and sequencing were performed on 3 µg of DNA extracted from the peripheral blood of three individuals (F102, F163 and F259). Enrichment was undertaken using the SureSelect Human All Exon kits following the manufacturer's protocol (Agilent Technologies), and samples were paired-end sequenced on either an Illumina HiSeq 2000 or SOLiD platform. Sequence data were mapped using BWA (Burrows-Wheeler Aligner) using the hg18 (NCBI36) human genome as a reference. Variants were called using SOAPsnp and SOAPindel (from the Short Oligonucleotide Analysis Package) with medium stringency ( Supplementary  Table 1 ).
Sanger sequencing.
Primers were designed to amplify the coding exons of IFIH1 ( Supplementary Table 7 ). Purified PCR amplification products were sequenced using BigDye Terminator chemistry and an ABI 3130 DNA sequencer. Mutation description is based on the reference cDNA sequence NM_022168.3, with nucleotide numbering beginning from the first A in the initiating ATG codon.
Gene expression analysis.
Total RNA was extracted from whole blood using a PAXgene (PreAnalytix) RNA isolation kit. RNA concentration was assessed using a spectrophotometer (FLUOstar Omega, Labtech). qPCR analysis was performed using TaqMan Universal PCR Master Mix (Applied Biosystems) and cDNA derived from 40 ng of total RNA. The relative abundance of target transcripts, measured using TaqMan probes for IFI27 (Hs01086370_m1), IFI44L (Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15 (Hs00192713_m1), RSAD2 (Hs01057264_m1) and SIGLEC1 (Hs00988063_m1), was normalized to the expression levels of HPRT1 (Hs03929096_g1) and 18S RNA (Hs999999001_s1) and assessed with Applied Biosystems StepOne Software v2.1 and DataAssist Software v.3.01. For each of the six probes, individual (case and control) data were expressed relative to a single calibrator (control C25). As previously described, the median fold change in expression of the 6 ISGs, when compared to the median expression for the 29 healthy controls combined, was used to create an interferon score for each case 9 . The RQ value is equal to 2 −∆∆Ct (i.e., normalized fold change relative to a control). When a subject was assayed on more than one occasion, the data for repeat measurements were combined to calculate a mean value (using Applied Biosystems DataAssist software v.3.01).
Statistics.
In the absence of a normal distribution, ISG levels and interferon scores were log transformed and analyzed using parametric testing (one-way ANOVA). Bonferroni or Dunnett's multiple-comparison tests were applied as detailed in Figure 2 and Supplementary Figure 4 . Interferon scores for each group were expressed as the median (IQR). Statistics were calculated using GraphPad Prism version 5.0d for Mac OS X.
Microsatellite genotyping. To confirm maternity and paternity, informative polymorphic microsatellite markers on chromosomes 3 (D3S3640 and D3S3560), 11 (D11S4205, D11S913, D11S987 and D11S1889) and 20 (D20S847, D20S896 and D20S843) were genotyped using DNA from F102, F524_2, F647, F626, F237, F163 and respective parents, as well as from an unrelated control sample. DNA samples were amplified by standard PCR (primer sequences available upon request). Each amplicon was mixed with HiDi Formamide (Applied Biosystems) and 500 ROX Size Standard (Applied Biosystems) and run on the Genetic Analyzer 3010 capillary electrophoresis system. Results were analyzed with GeneMapper v4.1 software (Applied Biosystems).
Protein modeling. The IFIH1 substitutions p.Arg337Gly, p.Asp393Val, p.Gly495Arg, p.Arg720Gln, p.Arg779His and p.Arg779Cys all fell within the helicase domain of the protein. Molecular graphics figures were generated with PyMOL (Schrodinger) using the PDB coordinates (4GL2).
Interferon reporter assays. The pFLAG-CMV4 plasmid encoding IFIH1 has been described elsewhere 12 . The indicated mutations were introduced using KAPA HiFi DNA polymerase. HEK 293T cells (American Type Culture Collection, ATCC) were maintained in 24-well plates in DMEM (Cellgro) supplemented with 10% heat-inactivated FCS and 1% penicillin-streptomycin. Cells were tested for mycoplasma. At ~95% confluence, cells were cotransfected with pFLAG-CMV4 plasmids encoding wild-type or mutant IFIH1 (5 ng, unless mentioned otherwise), IFN-β promoter-driven firefly luciferase reporter plasmid (200 ng) and a constitutively expressed Renilla luciferase reporter plasmid (pRL-CMV; 20 ng) using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Medium was changed 6 h after transfection, and cells were subsequently stimulated with poly I:C (0.5 µg/ml; Invivogen) or with in vitro-transcribed 162-bp dsRNA (0.5 µg/ml) using Lipofectamine 2000. Cells were lysed 24 h after stimulation, and IFN-β promoter activity was measured using the Dual-Luciferase Reporter assay (Promega) and a Synergy2 plate reader (BioTek). Firefly luciferase activity was normalized against Renilla luciferase activity. Error bars represent s.d. from three independent experiments. For protein blot analysis, primary antibodies to Flag (F7425, Sigma-Aldrich; 1:1,000 dilution) and actin (A5441, Sigma-Aldrich; 1:1,000 dilution) were used together with horseradish peroxidase (HRP)-conjugated secondary antibodies to rabbit IgG (sc-2004, Santa Cruz Biotechnology) and mouse IgG (sc-358917, Santa Cruz Biotechnology), respectively.
Protein and RNA preparation. Wild-type IFIH1∆2CARD and variants were expressed from pET50 (Novagen) as a 6× His-tagged NusA fusion protein in BL21(DE3) as previously described for wild-type IFIH1 (ref. 12) . Briefly, cells were lysed by Emulsiflex, and proteins were purified by a combination of nickel-NTA (nitrilotriacetic acid) affinity, heparin affinity and size-exclusion chromatography in buffer A (20 mM HEPES, pH 7.5, 150 mM NaCl and 2 mM DTT). The NusA tag was removed from all proteins by human rhinovirus (HRV) 3C cleavage. Sequences for the 162-bp and 112-bp dsRNAs were taken from the first 150 and 100 nucleotides of the IFIH1 gene, respectively, flanked by 5′-GGGAGA-3′ and 5′-TCTCCC-3′. dsRNA was prepared as previously described 12 . Briefly, two complementary strands of dsRNA were cotranscribed using T7 RNA polymerase, and duplex RNA was separated from individual strands by 8-10% PAGE followed by electroelution. The 3′ end of purified 112-bp dsRNA was subsequently labeled with fluorescein hydrazide as previously described 14 .
Electrophoretic mobility shift assays and ATP hydrolysis assays. Assays were performed as previously reported 12 . Briefly, 3′ fluorescein-labeled 112-bp (20 nM) dsRNA 14 was incubated with protein (40-160 nM) in buffer B (20 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 and 2 mM DTT) in the presence or absence of 2 mM ATP, and complexes were analyzed on Bis-Tris NativePAGE (Life Technologies). Fluorescent gel images were recorded using the FLA9000 scanner and were analyzed with Multigauge (GE Healthcare). Curve fitting was performed using the KaleidaGraph program (Synergy). For ATP hydrolysis assays, IFIH1 (0.3 µM) was incubated with ATP (2 mM) and 112-bp dsRNA (0.6 µM) in buffer B at 37 °C. Use of an excess amount of 112-bp dsRNA (0.6 µM corresponds to 4.8 µM IFIH1-binding sites, as each 112-bp dsRNA molecule can accommodate 8 IFIH1 molecules) simplified the comparison of wild-type and mutant IFIH1 by focusing on intrinsic ATP hydrolysis activities, independent of dsRNA binding 12 . Reactions were quenched at 0 min and 5 min with 50 mM EDTA, and the levels of released phosphate were measured using GreenReagent (Enzo Lifescience) at optical density 600 (OD 600 ). 
